HopeStage
Back to all studies
CompletedNCT00191880

Atomoxetine and academic outcomes in children ages 8–11 with ADHD

About this titleRead the official source — NCT00191880
Medication studyAges 8–11Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 8 years to 11 years.

Listed locations
Calgary and 7 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2004
Recruitment status
Completed
Enrollment listed in the registry
100
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada
Age range
From 8 Years to 11 Years
Official registry ID
NCT00191880
Official title
Show the full official title

A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Calgary · Edmonton · London

5 more locations
  • Montreal
  • Saskatoon
  • Scarborough
  • St. Johns
  • Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including atomoxetine.

Who was this study for?

Listed age limits: 8 years to 11 years.

Want to explore more studies?

Explore studies